Hypoxia-inducible factor 1 signaling pathway (HIF-1 signaling pathway)

The **HIF‑1 signaling pathway** is a cellular signal transduction cascade centered on hypoxia-inducible factor 1 (HIF‑1), a heterodimeric transcription factor that acts as a master regulator of oxygen homeostasis in mammals[1][3][6]. The core functional unit consists of two subunits: an inducibly-expressed alpha subunit (**HIF‑1α**) and a constitutively-expressed beta subunit (**HIF‑1β**, also known as ARNT)[3][6]. Under normal oxygen conditions (*normoxia*), HIF‑1α is hydroxylated and rapidly degraded via ubiquitination. In low oxygen (*hypoxic*) environments, this degradation is inhibited; stabilized HIF‑1α accumulates in the nucleus where it dimerizes with HIF‑1β and binds DNA at hypoxia response elements to activate transcription of numerous genes involved in adaptation to hypoxic stress[3][6]. The **biological functions** regulated by this pathway include angiogenesis, erythropoiesis, glucose metabolism reprogramming toward glycolysis (“Warburg effect”), cell survival under stress conditions, and modulation of immune responses[3][5][6]. Dysregulation or overactivation contributes significantly to cancer progression—by promoting tumor vascularization and metabolic adaptation—as well as cardiovascular diseases such as ischemia-reperfusion injury[4][5]. While many drugs have been developed that target key proteins within this cascade—such as **roxadustat**, **daprodustat**, **vadadustat** (all prolyl hydroxylase inhibitors stabilizing HIF for anemia treatment), or investigational anti-cancer agents like YC‑1—the “HIF–1 signaling pathway” itself is not considered a single molecular therapeutic target but rather describes an interconnected network involving multiple potential drug targets[2][4][5]. Therefore: > The “HIF–1 signaling pathway” is not itself a molecule or receptor but refers collectively to all molecular events downstream from activation/inhibition of hypoxia-inducible factors. For structured data purposes, it should be mapped instead to its principal effector protein(s)—most commonly “Hypoxia-inducible factor 1-alpha” (*HIFA*, *Hif‐alpha*, *Hif‐a*, gene symbol *HIFIA*)—which are valid therapeutic targets. If you require information about specific druggable entities within this system—for example “Hypoxia-inducible factor 1-alpha”—please specify so structured data can be provided for those canonical targets. **Note:** This entry should be flagged `is_incorrect = true` because “signaling pathways” are not themselves discrete molecular targets suitable for direct pharmacological intervention; only their constituent molecules qualify under standard conventions[2].

Other names

HIF-1 pathwayHypoxia-inducible factor 1 pathwayHIF-1α signaling (when referring to the alpha subunit)